M3 Presentation Material

Jan. 2014



Copyright © 2013 M3, Inc. All rights reserved.

The following contains statements that constitute forward-looking statements, plans for the future, management targets, etc. relating to M3, Inc. and/or its group. These are based on current assumptions of future events, and there exist possibilities that such assumptions are objectively incorrect and actual results may differ from those in the statements as a results of various factors.

Furthermore, information and data other than those concerning the Company and its subsidiaries/affiliates are quoted from public information, and the Company has not verified and will not warrant its accuracy or dependency.

M3, Inc.

Company Background

Nm

Business domain


Internet-based healthcare businesses

Name	
→ M3 <u>M</u> edicine <u>M</u> edia <u>M</u> etamorphosis	


History

2000	Sep	Founded
	Oct	Launched MR-kun service
2002	Mar	Acquired WebMD Japan
2004	Sep	Listed on TSE Mothers
2005	Мау	Alliance with Medi C&C and entry into Korean market
	Sep	Launched QOL-kun service
	Dec	Launched AskDoctors service
2006	Jun	Acquired MDLinx and entered into US market
2007	Mar	Listed on TSE 1
2008	Oct	Opened "MedQuarter.de" to enter into Europe market
2009	Apr	Acquired Mebix and entered into clinical trial market
2010	Nov	Acquired EMS Research and established global research physician panel
2011	Aug	Acquired Doctors.net.uk and entered into UK market
2013	Nov	Entered into China market

m3.com



M3's Growth




Japanese Pharma's Huge Marketing Costs

	Head count		Annual costs per person		
MRS (Pharmaceutical companies)	63,000	╳	¥20mn	e ¥1.2tn	Total cost of whole industry ¥1.2-1.5 tn
MSs (Pharmaceutical wholesalers)	30,000	×	¥10mn	e ¥300bn	


Physicians' Demand for On-Line Detailing

Q. What is the ideal ratio of on-line and off-line promotional information ("details") from pharma companies?



Demand for eDetails is quite high for busy physicians as they can get information when it's convenient for themselves, not for MRs

Source: M3 questionnaire to 1,300 physicians




Case


study

MR-kun Annual Fee Structure




MR-kun's Growth Potential in Japan





Consolidated Sales Trend




New Business Development on the Platform (as of Mar. 2010)



Total revenue of new businesses was less than 5 billion yen. This was just after establishing M3 Career and at this time only Mebix was offering our evidence solution service


Copyright © 2014 M3, Inc. All rights reserved.

New Business Development on the Platform



Total revenue of new businesses in FY2013 will be more than 18 billion yen. Planning 10 to 20 new business ideas and overseas development.


New Business Development on the Platform



Placing Evidence Solution Business in Our Strategy


"Making use of the Internet to increase, as much as possible, the number of people who can live longer, healthier and happier lives, and to reduce, as much as possible, the amount of unnecessary medical costs"






Patient Enrollment in a Large-Scale Clinical Trial Case study

In the case of study in the Endocrinology and Metabolism area, m3.com doctors enrolled five times more patients than those of other SMOs:



Shift to Online Trials



Number of CRAs by Company

#	Company Name	Number		M3 Group
1	EPS	855		- •
2	Cimic	780		
	M3 Group	670	-	1
3	Quintiles	600	-	
4	Parexel	550		
5	MEDISCIENCE PLANNING INC	401		
6	MIC Medical	233	-	
7	ACRONET	200		
8	ASKLEP	180		_
9	Linical	170		
	Mebix	36		


<MIC research institute ltd>




Accelerate the "Shift to Online Trials" by reaching a top level in number of CRAs. Business size of evidence solution segment will grow to 13B yen

Sales and Profit Trend of Evidence Solution

<Mil yen>




New Business Development on the Platform




Sales and Profit Trend of M3 Career


<Mil yen>



- Improvement in operation efficiency
- Development of newly-hired staff in productivity
- staff agency service for physicians should be several billions yen in the future



Physicians Registered in Our Site or Research Panel (Global)




Development in the US



- "M3 Messages" (US version of MRkun) started on MDLinx (merged with M3 USA in Mar. 2009).
 - Washington D.C.
 - Extended reach to nearly 600,000
 US physicians, covering 80% of
 US physicians
- Gradually expanding career service in addition to marketing support service and research service
- In the future, planning to monetize 500K physician members of MDLinx who are outside of the USA

Sales and Profit Trend of Overseas

<Mil yen>




Improving performance with increasing media power of our sites

- Pharmaceutical companies are becoming aggressive about e-promotion
- Estimate +50% growth in sales this fiscal year
- Impact from the partnership with PDR should realize in the future


Market Potential in China (researched by M3)

Digital marketing for medical products in China




Strategic Direction of M3


Changing Strategy in New Business Development



Value Creation via M&A




CSO Market



- Size of Japanese CSO market is about ¥50B
- Number of contract MRs is increasing by 23.9% annually
- Not only mega pharma but generic companies, medical device companies and animal health companies are starting to use CSO


CSO service armed with internet




Provide differentiated CSO service. Growth potential could be billions of yen business size in the future

Financial Result

Consolidated P/L Statement for FY2013 3Q



Quarterly Performance of Ordinary Profit (vs PY)



Higher growth ratio than FY2012 since each business is growing steadily


Consolidated P/L Statement for FY2013 1Q-3Q

1

Breakdown by Business Segments				
(Mil yen)		FY2012 1Q-3Q	FY2013 1Q-3Q	YoY Growth
Medical Portal	Sales	12,072	14,732	+22%
	Profit	6,904	8,276	+20%
Evidence	Sales	2,967	4,964	+67%
Solution	Profit	366	1,027	+180%
Overseas	Sales	2,931	4,590	+57%
	Profit	139	711	+409%
Clinical	Sales	360	2,030	+464%
Platform	Profit	▲3	232	-
Others	Sales	576	749	+30%
	Profit	45	90	+100%


Consolidated Sales Analysis (vs P.Y.)

(Mil yen)




INST Steady growth momentum continues

Annual Results & Forecast for FY2013



Creating New Value in Healthcare



→ M3 <u>M</u>edicine <u>M</u>edia <u>M</u>etamorphosis

- → Healthcare sector is huge...
- Japanese national spending on medical services is approximately ¥33tn (approximately ¥50tn if peripheral businesses are included)
- Equivalent to 10% of Japanese GDP
- Sector controlled by only 290,000 people, e.g., physicians, representing only 0.2% of the population
- → M3 aims to create new value in this sector
- Solve the issues and problems of the medical sector
- With new and unique business models
- While focusing on areas were we can add high value (e.g., have high profit) to boost our enterprise value